These biotech companies have catalysts ahead.

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday. ・Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October. ・Retail ...

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

The average one-year price target for Krystal Biotech (NasdaqGS:KRYS) has been revised to $269.93 / share. This is an increase of 18.96% from the prior estimate of $226.90 dated December 18, 2025. The ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind Rogaine—is well coiffed to tap into the increasingly lush opportunity for hair r | ...

Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...